

HR 4906

Insulin Price Reduction Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 29, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 30, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4906>

Sponsor

Name: Rep. DeGette, Diana [D-CO-1]

Party: Democratic • **State:** CO • **Chamber:** House

Cosponsors (54 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Reed, Tom [R-NY-23]	R · NY		Oct 29, 2019
Rep. Allred, Colin Z. [D-TX-32]	D · TX		Nov 1, 2019
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Nov 12, 2019
Rep. Garcia, Sylvia R. [D-TX-29]	D · TX		Nov 12, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		Nov 12, 2019
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Nov 22, 2019
Rep. Davids, Sharice [D-KS-3]	D · KS		Dec 19, 2019
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Feb 14, 2020
Rep. Harder, Josh [D-CA-10]	D · CA		Feb 14, 2020
Rep. McAdams, Ben [D-UT-4]	D · UT		Feb 14, 2020
Rep. Stevens, Haley M. [D-MI-11]	D · MI		Feb 14, 2020
Rep. Wild, Susan [D-PA-7]	D · PA		Feb 14, 2020
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Feb 28, 2020
Rep. Dingell, Debbie [D-MI-12]	D · MI		Feb 28, 2020
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Feb 28, 2020
Rep. Maloney, Sean Patrick [D-NY-18]	D · NY		Feb 28, 2020
Rep. Price, David E. [D-NC-4]	D · NC		Feb 28, 2020
Rep. Rose, Max [D-NY-11]	D · NY		Feb 28, 2020
Rep. Wasserman Schultz, Debbie [D-FL-23]	D · FL		Feb 28, 2020
Rep. Waters, Maxine [D-CA-43]	D · CA		Feb 28, 2020
Rep. Axne, Cynthia [D-IA-3]	D · IA		Mar 5, 2020
Rep. Boyle, Brendan F. [D-PA-2]	D · PA		Mar 5, 2020
Rep. Cicilline, David N. [D-RI-1]	D · RI		Mar 5, 2020
Rep. Clay, Wm. Lacy [D-MO-1]	D · MO		Mar 5, 2020
Rep. Connolly, Gerald E. [D-VA-11]	D · VA		Mar 5, 2020
Rep. Davis, Danny K. [D-IL-7]	D · IL		Mar 5, 2020
Rep. Deutch, Theodore E. [D-FL-22]	D · FL		Mar 5, 2020
Rep. Higgins, Brian [D-NY-26]	D · NY		Mar 5, 2020
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Mar 5, 2020
Rep. Lee, Susie [D-NV-3]	D · NV		Mar 5, 2020
Rep. Lowey, Nita M. [D-NY-17]	D · NY		Mar 5, 2020
Rep. McCollum, Betty [D-MN-4]	D · MN		Mar 5, 2020
Rep. Perlmutter, Ed [D-CO-7]	D · CO		Mar 5, 2020
Rep. Pingree, Chellie [D-ME-1]	D · ME		Mar 5, 2020
Rep. Schrier, Kim [D-WA-8]	D · WA		Mar 5, 2020
Rep. Soto, Darren [D-FL-9]	D · FL		Mar 5, 2020
Rep. Aguilar, Pete [D-CA-31]	D · CA		May 27, 2020
Rep. Ruppersberger, C. A. Dutch [D-MD-2]	D · MD		May 27, 2020
Del. San Nicolas, Michael F. Q. [D-GU-At Large]	D · GU		Jun 22, 2020
Rep. Castro, Joaquin [D-TX-20]	D · TX		Jun 22, 2020
Rep. Craig, Angie [D-MN-2]	D · MN		Jun 22, 2020

Cosponsor	Party / State	Role	Date Joined
Rep. Hayes, Jahana [D-CT-5]	D · CT		Jun 22, 2020
Rep. Jackson Lee, Sheila [D-TX-18]	D · TX		Jun 22, 2020
Rep. Kelly, Mike [R-PA-16]	R · PA		Jun 22, 2020
Rep. Larson, John B. [D-CT-1]	D · CT		Jun 22, 2020
Rep. Payne, Donald M., Jr. [D-NJ-10]	D · NJ		Jun 22, 2020
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Jul 9, 2020
Rep. Cohen, Steve [D-TN-9]	D · TN		Jul 9, 2020
Rep. Garcia, Jesus G. "Chuy" [D-IL-4]	D · IL		Jul 9, 2020
Rep. Luria, Elaine G. [D-VA-2]	D · VA		Jul 9, 2020
Rep. Thompson, Bennie G. [D-MS-2]	D · MS		Jul 9, 2020
Rep. Serrano, Jose E. [D-NY-15]	D · NY		Jul 31, 2020
Rep. Gonzalez, Vicente [D-TX-15]	D · TX		Sep 11, 2020
Rep. Velazquez, Nydia M. [D-NY-7]	D · NY		Sep 11, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 30, 2019
Ways and Means Committee	House	Referred To	Oct 29, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 2199	Related bill	Jul 22, 2019: Read twice and referred to the Committee on Finance.

Insulin Price Reduction Act

This bill prohibits health insurance plan issuers and pharmacy benefits managers (PBMs) from receiving rebates or discounts for insulin from manufacturers who certify that its current insulin list price has been reduced to an amount no greater than what the list price was for the same insulin on July 1, 2006. This restriction does not apply to discounts provided to insurance plan holders at retail sale or to flat-rate fees for service paid to PBMs. Further, insurance plans are prohibited from applying a deductible to insulin that has received such price certification.

A manufacturer may certify insulin prices by submitting to the Department of Health and Human Services data about the list price of any insulin the manufacturer has produced since January 1, 2000, and by setting the current list price for an insulin product at the 2006 rate. To remain certified, a manufacturer may not increase the list price of insulin by more than the annual increase in the medical care consumer price index. A manufacturer may certify the price of an insulin product for which it did not have a list price in 2006 by reducing the list price of such insulin to the weighted average list price in 2006 of specified insulin categories.

This bill also applies to Medicare prescription drug benefits. The bill sets the rebate for insulin under Medicaid based on the average manufacturer price of insulin during the last fiscal quarter of 2019, increasing by the medical care consumer price index thereafter.

Actions Timeline

- **Oct 30, 2019:** Referred to the Subcommittee on Health.
- **Oct 29, 2019:** Introduced in House
- **Oct 29, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.